The large pivotal CREDENCE, DAPA-CKD, and EMPA-KIDNEY RCTs demonstrated that the efficacy of SGLT-2 inhibitors is independent of the presence or absence of T2DM and of the baseline eGFR under study. Here, SLC5A2 is linked to type 2 diabetes mellitus.